Anti-Tau Immunotherapy Dosing Optimization

V2, Crosslink

🧫

Anti-Tau Immunotherapy Dosing Optimization

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-anti-tau

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Anti-Tau Immunotherapy Dosing Optimization ## Background and Rationale This clinical optimization study focuses on establishing optimal dosing regimens for tau-targeting immunotherapies in Alzheimer's disease patients. Given the critical role of tau pathology in AD progression and the promising but variable results from early-phase tau immunotherapy trials, this research addresses the urgent need for evidence-based dosing strategies. The study employs a systematic dose-escalation design to eva

METHODOLOGY NOTES

**Phase 1: Patient Recruitment and Screening (Months 1-3)** • Recruit 240 patients with mild-to-moderate Alzheimer's disease (MMSE 14-26, CDR 0.5-2.0) • Conduct comprehensive screening including tau-PET imaging, CSF biomarkers (p-tau181, p-tau217), MRI, neuropsychological assessment • Exclude patients with active autoimmune conditions, previous immunotherapy exposure, or contraindications to MRI • Stratify patients by baseline tau burden (low: <1.5 SUVR, moderate: 1.5-2.0 SUVR, high: >2.0 SUVR) **Phase 2: Randomization and Baseline Assessment (Month 4)** • Randomize patients to 6 treatment arms (n=40 each): placebo, anti-tau antibody at 0.5mg/kg Q4W, 1.0mg/kg Q4W, 2.0mg/kg Q4W, 1.0mg/kg Q2W, 2.0mg/kg Q2W • Collect baseline measurements: ADAS-Cog13, CDR-SB, ADCS-ADL, tau-PET SUVR, CSF p-tau levels, plasma NfL, brain volume via MRI • Establish safety monitoring committee with predefined stopping rules **Phase 3: Treatment Administration (Months 5-16)** • Administer intravenous anti-tau

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.907277Z'}
summary	# Anti-Tau Immunotherapy Dosing Optimization ## Background and Rationale This clinical optimization study focuses on establishing optimal dosing regimens for tau-targeting immunotherapies in Alzheimer
entities	{'genes': ['ADRA2A/HSP90AA1/LRP1'], 'diseases': ["Alzheimer's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Dose-dependent reduction in tau-PET signal measured by longitudinal [18F]MK-6240 or [18F]PI-2620 PET imaging at 12 months compared to baseline.
methodology_notes	Phase 1: Patient Recruitment and Screening (Months 1-3) • Recruit 240 patients with mild-to-moderate Alzheimer's disease (MMSE 14-26, CDR 0.5-2.0) • Conduct comprehensive screening including tau-P
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.907284', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

617

Outgoing

490

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Anti-Tau Immunotherapy Dosing Optimization

derives from (16)

supports (5)

💬 Discussion